Www.pharm.monash.edu.au/mips FADDI RAJESH V. DUDHANI, JIAN LI, ROGER L. NATION Facility for Anti-infective Drug Development & Innovation Drug Delivery,

Slides:



Advertisements
Similar presentations
Photo edit Edit: Change the photo by marking the background plane (picture) in the grouped objects. The object (picture) is marked with grey corners when.
Advertisements

Modern Tools for Drug Discovery NIMBUS Biotechnology Modern Tools for Drug Discovery
Younas Masih RN, Post RN BSc.N (Lecturer ) New Life College Of Nursing Karachi 11/7/20141Antimicrobial medications.
Pharmacodynamics of MASKO Compounds (Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones) William A. Craig, MD University of Wisconsin.
Animal Model PK/PD: A Tool for Drug Development
1 Benoît GUERY Infectious Diseases CHRU Lille Antibiotic strategies How to treat Multi-drug-resistant Pseudomonas.
American Conference on Pharmacometics –San Diego, CA; April Population PK modeling incorporating enzyme induction mechanism to guide the design.
Pharmacodynamics and the Dosing of Antibacterials
Jörg KeldenichNov PhysChem Forum 1 Physicochemical Properties at Bayer HealthCare (Wuppertal) and Their Use in Medicinal Chemistry.
5/20/2015ISAP Is the cellular accumulation of antibiotics a predictive factor for intracellular efficacy ? Sandrine Lemaire Université catholique.
Population PK/PD analysis of the bactericidal activity of sutezolid and its major metabolite against intracellular Mtb in whole blood cultures of TB patients.
Monash Institute of Pharmaceutical Sciences Sheep as a clinically relevant model to assess the pharmacokinetics of colistin and colistin methanesulfonate.
Improvement in Dose Selection Through Clinical Applications of PK/PD in Antimicrobial Drug Development Hartmut Derendorf, Ph.D. University of Florida.
Eccmid 2003 Aminoglycosiden bij neonaten Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton Relationship between bacterial killing,
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
The Relationship between Daptomycin (DAP) Free drug AUC/MIC, Antibacterial effect (ABE) and Emergence of Resistance (EoR) in S.aureus. KE Bowker, AR Noel,
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Pharmacodynamics of Antibiotics
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Pharmacodynamics of Glycopeptides Niels Frimodt-Møller, MD DMSc Dept. Of Microbiological R & D Statens Serum Institut, Copenhagen, Denmark.
PK/PD: New Microbial Diseases and Model Systems Tawanda Gumbo, MD Associate Professor of Medicine, Division of Infectious Diseases, University of Texas.
Confidential Corporate presentation, April Confidential Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
MethodsAbstract Methods Results Printed by Novel 8-Heterocyle Substituted Tetracyclines are Potent and Broad Spectrum Antibacterial Agents with Oral Bioavailability.
Martina Sahre1, Sreedharan Sabarinath1, PhD Maria Grant2, MD,
Application of PK/PD modeling for optimization of linezolid therapy Julia Zayezdnaya Zack.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.
PK/PD - ICC - Manila, June 5th, The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul.
Use of in vitro models to study the emergence of resistance Professor Inga Odenholt Department of Infectious Diseases University hospital, Malmö Sweden.
William A. Craig Symposium ISAP Research Meeting PK/PD and Genomics David Andes University of Wisconsin.
SALIVARY, PROTEIN UNBOUND AND TOTAL PLASMA CONC OF RIFAMPICIN HADIJA H SEMVUA 11/12/2015KCRI_PhD SYMPOSIUM
Preclinical Models to Support Dosage Selection
Pharmacokinetics of Antimicrobials in Animals: Lessons Learned William A. Craig, M.D. University of Wisconsin-Madison.
The Endpoint from a Resistance Point of View A Symposium to Honor the Career of William A. Craig, M.D. George Drusano, M.D. Co-Director Ordway Research.
Antibiotics Broad Spectrum vs Narrow Spectrum. Two Groups of antibiotics An antibiotic may be classified basically as "narrow- spectrum" or "broad-spectrum"
Enfuvirtide for Drug-Resistant HIV Infection in North and South America Simon R. Bababeygy.
Prof. Hartmut Derendorf University of Florida The Role of Pharmacological Predictors in Drug Development.
Animal Models in Early Evaluation of Antibacterial Agents
Pharmacodynamics of Antifungals
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
1 Motivation and philosophy for development of mechanistic PK/PD models in infectious diseases William A. Craig Symposium October 29 th 2008 University.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.
Pk/Pd modelling : Clinical Implications
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology.
JWM Grindelwald Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands Johan W. Mouton Pharmacodynamic Indices.
The Efficacy of Topical Manuka Honey and Combination Antibiotic Therapy in the Treatment of MRSA Skin Infections Kyle Liban Pacific University School of.
Colistin Re-emerging antibiotics VS Adverse effects – respiratory failure 1 R4 김선혜 / Fellow. 임효석.
Operations  Started research operations (10 FTEs) in September 2011  Redx Anti-Infectives launched in Alderley Park in April 2013  Currently 55 scientists.
Comparison of the intracellular and extracellular activities of approved and novel antistaphylococcal antibiotics using a pharmacodynamic model exploring.
In vitro pharmacodynamic models for the study of antibiotic activity against bacterial biofilms Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire.
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular.
FUS, VAN and LZD injected twice (T0 and T12); DAP injected once (T0).
Introduction Results Aim Methods References Conclusion
Background and objectives
Emilien Drouot, Paul M. Tulkens, Françoise Van Bambeke
COLISTIN: what is new for an old antibiotic ?
Incubation (with antibiotic)
Antibiotics and Antibiotic Resistance
Optimizing Aminoglycoside Use
Correspondence: Bactericidal Activity of Fosfomycin against NDM-1 producing Enterobacteriaceae M. Albur, A. Noel, K. Bowker, A.
Introduction: Results: Methodology: Discussion: Conclusion:
in Broth Microdilution Method. M. Albur, A. Noel, K. Bowker, A
Madam Therapeutics Next generation antibiotics to fight global anti-microbial resistance November 2017.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin- resistant Acinetobacter baumannii  X. Vila-Farres, C. Garcia.
Pharmacokinetics and pharmacodynamics of fluoroquinolones
Figure 1. Recombinant mouse immunoglobulin G2a (IgG2a) monoclonal antibody rMAb 3F6 neutralizes staphylococcal protein A (SpA), promotes opsonophagocytic.
Presentation transcript:

FADDI RAJESH V. DUDHANI, JIAN LI, ROGER L. NATION Facility for Anti-infective Drug Development & Innovation Drug Delivery, Disposition and Dynamics Monash Institute of Pharmaceutical Sciences ISAP Post-ICAAC Symposium, 15 September, 2009 San Francisco Concentration-dependent Plasma Binding of Colistin: Impacts of Infection, Neutropenia & Multiple Proteins

Outline Background Methods Results and Discussion Conclusions

Outline Background Methods Results and Discussion Conclusions

Gram-negative ‘superbugs’: Acinetobacter baumannii Klebsiella pneumoniae Pseudomonas aeruginosa Virtually NO antibiotics active against G-negatives in next years Currently, colistin often the only active antibiotic The threat from the PINK corner IDSA 2004, 2006, 2009 Livermore Ann Med 2003 Payne et al. Nat Rev Drug Discov 2007

Colistin Colistin (polymyxin E) Antibacterial activity  Narrow spectrum: G-neg bacteria (P. aeruginosa, A. baumannii and K. pneumoniae)  Rapid bactericidal effect: Concentration-dependent  Very modest PAE against P. aeruginosa Currently resistance is low, but emerging Li et al. Lancet Infect Dis 2006

Colistin Colistin A: 6-methyloctanoic acid Colistin B: 6-methylheptanoic acid Dab: ,  -Diaminobutyric acid multi-component a weak organic base containing 5 primary amine groups polycation at physiological pH Li et al. Lancet ID 2006

Colistin PK/PD index against P. aeruginosa in an in vitro dynamic model P. aeruginosa ATCC and PAO1 Bergen et al. submitted Killing Effect fAUC/MIC R 2 = 93% R 2 = 70% R 2 = 81% fC max /MIC

Higher plasma binding of polymyxin B in critically-ill patients mg/kg every 12 or 48 h Cao et al, JAC 2008 Zavascki et al, CID 2009 MICs Protein binding % vs 56% in healthy human plasma

Plasma binding of drugs Crucial to understanding of PK/PD relationship Two plasma proteins commonly involved Human serum albumin (HSA): binds weak organic acids & bases and neutral compounds alpha-1-acid glycoprotein (AAG) o the acute-phase reactant protein o often important for the binding of weak organic basic drugs o plasma concentrations of AAG (~0.75 g/L) are normally much lower than those of HSA (~45 g/L) o concentrations of AAG are increased (~3-5 fold) in a number of stressful conditions, including infection

Aims To investigate the proteins involved in the plasma binding of colistin To examine the potential impact of colistin concentration on its plasma binding

Outline Background Methods Results and Discussion Conclusions

Methods Healthy human plasma (Australian Red Cross) Mouse plasma o Six-week old, female Swiss albino mice ( g) were rendered neutropenic by IP cyclophosphamide (150 mg/kg) 4 days and (100 mg/kg) 1 day prior to experimental infection o Neutropenic mice were anesthetized and 50 µL early log-phase P. aeruginosa ATCC (~10 7 CFU) was injected into each posterior thigh o At 6 h, animals were humanely sacrificed & plasma was obtained

Methods Purified protein solutions in isotonic phosphate buffer (pH 7.4) o HSA: 22.5 g/L & 45 g/L o AAG: 0.75 g/L & 3 g/L o AAG/HSA: 0.75 g/L / 45 g/L; 3 g/L / 45 g/L Equilibrium dialysis o Spectra Por 2 ® dialysis membrane (MW cut off 12, ,000) o Colistin-spiked plasma or solutions of purified protein(s) were dialyzed at 37ºC for 21 h o Initial colistin conc: 3 mg/L (low) & 30 mg/L (high) o In neutropenic infected mouse plasma, initial colistin conc 2.5 – 75 mg/L

Methods Colistin concentrations in the protein and buffer solutions were determined using a validated HPLC assay The unbound fraction (f u ) of colistin was calculated from the ratio, at dialysis equilibrium, of concentration in buffer to that in the protein-containing solution

Outline Background Methods Results and Discussion Conclusions

Plasma binding of colistin: proteins involved Concentration dependent AAG and HSA Healthy human plasma vs physiological concentrations of HSA/AAG Low colistin concentrations: mg/L High colistin concentrations: mg/L

Plasma binding of colistin in mice Mouse plasma Neutropenic mouse plasma Neutropenic infected mouse plasma f u in healthy mouse plasma is similar to that in healthy human plasma f u in neutropenic and neutropenic infected mouse plasma are lower Low concentrations: mg/L High concentrations: mg/L

Conc-dependent plasma binding of colistin in mice Dudhani et al. A1-576 Neutropenic infected mouse plasma Colistin concentration range (~0.9 – 30 mg/L) f u increased ~4-5 fold as plasma concentration increased

Outline Background Methods Results and Discussion Conclusions

Both HSA and AAG are important in the binding of colistin in plasma AAG conc increases in infections increased plasma binding of colistin Colistin binding was dependent upon its concentration Similar fAUC/MIC values from in vitro PK/PD model and mouse thigh infection model Assist in defining optimal dosage regimens for colistin Further investigation on colistin binding affinity, capacity to plasma proteins and bacterial cells is warranted

Acknowledgements FADDI team NIH/NIAID R01AI and R01AI Australian National Health & Medical Research Council